K. Conway

发表

NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded.

P. Lansbury, P. Weinreb, W. Zhen, 1996, Biochemistry.

Virus-Based Expression Systems Facilitate Rapid Target In Vivo Functionality Validation and High-Throughput Screening

Zina Itkin, Mary Jo Wildey, Sergey E. Ilyin, 2003, Journal of biomolecular screening.

Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.

P. Lansbury, J. Rochet, K. Conway, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct

Peter T. Lansbury, Jean-Christophe Rochet, P. Lansbury, 2001, Science.

Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease

Peter T. Lansbury, P. Lansbury, K. Conway, 1998, Nature Medicine.

Accelerated Oligomerization by Parkinson's Disease Linked α‐Synuclein Mutants

P. Lansbury, J. Rochet, S.-J. Lee, 2000 .

Monoamine oxidase binding not expected to significantly affect [18F]flortaucipir PET interpretation

M. Pontecorvo, K. Conway, Qianwa Liang, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic mice

D. Scheuner, S. Kahn, R. Hull, 2018, Diabetologia.

Monoamine oxidase binding not expected to significantly affect [18F]flortaucipir PET interpretation

M. Pontecorvo, K. Conway, Qianwa Liang, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Emerging β-Amyloid Therapies for the Treatment of Alzheimer's Disease

K. Conway, A. Reitz, K. Felsenstein, 2003 .

Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants.

P. Lansbury, J. Rochet, K. Conway, 2000, Annals of the New York Academy of Sciences.

2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead.

Junya Qu, Allen B Reitz, Brett A Tounge, 2007, Journal of medicinal chemistry.

Synthesis of (-)-5,8-dihydroxy-3R-methyl-2R-(dipropylamino)-1,2,3,4-tetrahydronaphthalene: an inhibitor of beta-amyloid(1-42) aggregation.

Robert H. Chen, D. H. Lee, S. Nortey, 2002, Bioorganic & medicinal chemistry.

Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads.

M. Vandermeeren, M. Mercken, C. Ho, 2010, Bioorganic & medicinal chemistry letters.

DIVERSITY AND CONTRASTIVITY IN PROSODIC AND SYLLABIC DEVELOPMENT

Suneeti Nathani Iyer, D. Oller, E. Buder, 2007 .

Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.

P. Lansbury, K. Conway, J. Harper, 2000, Biochemistry.

Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein.

P. Lansbury, J. Rochet, K. Conway, 2000, Biochemistry.

Interactions among α-synuclein, dopamine, and biomembranes

P. Lansbury, S. Lindquist, H. Lashuel, 2007, Journal of Molecular Neuroscience.

Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease.

Jean-Christophe Rochet, Peter T Lansbury, P. Lansbury, 2004, Journal of molecular neuroscience : MN.